Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Open access
Wang, Weihao, Liu, Hongyan, Xiao, Shumin, Liu, Shuaihui, Li, Xin, Yu, Pei · 2017 · Diabetes Therapy

Abstract

INTRODUCTION: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) has already been proven an efficient treatment option for type 2 diabetes. This combination can effectively improve glycated hemoglobin levels, cause weight loss and reduce the dosage of insulin. In addition, it can also reduce the risk of hypoglycemia. Several randomized controlled trials have confirmed that this treatment may be just as effective for type 1 diabetes mellitus (T1DM) patients. The objective of this meta-analysis was to assess the effects and efficacy of the treatment on glycemic changes, weight loss and insulin dosage in type 1 diabetes mellitus patients. METHODS: We searched Embase, PubMed and Cochrane for randomized controlled trials (no time restrictions) that investigated combined insulin and GLP-1 treatment. The main endpoints were measurements of glycated hemoglobin and changes in the weight and the dosage of insulin. RESULTS: In total, 1093 were studies identified, and 7 studies were included in our meta-analysis. GLP-1 agonist and insulin combination therapy led to greater reductions in HbA1c levels [P = 0.03; mean difference -0.21; 95% confidence intervals (CI) (-0.40, 0.02)] and weight [P < 0.05; -3.53 (-4.86, 2.19)] compared to control treatments. The combination therapy did not significantly influence the daily weight-adjusted total insulin dose [P = 0.05; -0.11 (-0.23, 0)], but it did reduce the daily weight-adjusted bolus insulin dose [P = 0.001; -0.06 (-0.1, 0.02)]. CONCLUSION: Our meta-analysis supports the use of a combined therapeutic regimen of insulin and GLP-1RAs for treating patients with T1DM. Combination therapy with GLP-1 and insulin could achieve an ideal treatment effect on glycemic control, weight loss and bolus insulin dose in patients with T1DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-017-0282-3

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Selection process for the included studies
Fig. 1 Selection process for the included studiesCC BY-NC · PubMed Central
Fig. 2 Assessment of bias among the included studies
Fig. 2 Assessment of bias among the included studiesCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Hamamoto Y, Mori K, Honjo S, et al. One-year effects of liraglutide on pancreatic beta cell function and glycemic control in Japanese type 1 diabetes with residual insulin secretion. Diabetologia. 2012;55:S300.

Cited by

See all 70

Metadata

Authors
Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P.
Affiliations
Tianjin Medical University (CN)
Corresponding author
Yu, Pei
Venue
Diabetes Therapy
Published
2017-06-14
Volume
8
Issue
4
Pages
727-738
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2626839453
Cited by
70
References
38
Citations by year
2026: 6 · 2025: 7 · 2024: 9 · 2023: 6 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 2 · 2018: 6 · 2017: 2
FWCI
0.80
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Tianjin Health Industry Key Research Projects (15KG101)
  • Tianjin Science and Technology Support Project (13ZCDSY01300)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
type 1 diabetes, insulin, GLP-1 receptor agonists, combination therapy, glycemic control, HbA1c, weight loss, insulin dose reduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1007/s13300-017-0282-3
The paper
Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017). Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-017-0282-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.